Caitlin John’s ImmunityBio IBRX Stock Holding History

Caitlin John’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.83K	Hold	500	–	–	﹤0.01%	650
2025 Q4	$990	Sell	500 -500	-50%	-$1.13K	﹤0.01%	801
2025 Q3	$2.46K	Buy	+1,000	New	+$2.58K	﹤0.01%	666

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Caitlin John's IBRX Position: Q1 2026 in Review

Caitlin John held its ImmunityBio (IBRX) position steady in Q1 2026 at 500 shares worth $3.83K. The position accounts for ﹤0.01% of the portfolio, ranked #650.

Caitlin John first reported a position in IBRX in Q3 2025 and has held it in 3 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Caitlin John held 500 shares of ImmunityBio worth $3.83K as of Q1 2026.
Caitlin John left its ImmunityBio share count unchanged in Q1 2026.
ImmunityBio made up ﹤0.01% of Caitlin John's portfolio in Q1 2026, its #650 holding.
Caitlin John first reported a position in ImmunityBio in Q3 2025 and has held it in 3 quarters since.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.